Nanoparticle isoflavone compositions & methods of making and using the same
AssigneeHumanetics Corporation
InventorsEdmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
Life of this patent
Estimating the term…
Abstract
The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
Claims22
1-64. (canceled)
A method of preventing the onset of or treating acute radiation syndrome, the method comprising:
- administering a therapeutically effective amount of a genistein formulation to a subject that has experienced exposure to radiation of at least 0.3 Gray or 30 rads,
- the genistein formulation comprising:
- (i) nanoparticulate genistein;
- and (ii) a pharmaceutically acceptable suspension medium comprising an aqueous carrier,
- wherein the nanoparticulate genistein exhibits a particle size distribution characterized by a D (0.50) of 0.5 μm or less, and
- wherein the nanoparticulate genistein is present in the formulation at a concentration of between 250 mg/ml and 500 mg/ml.
A method of prophylactically treating exposure to radiation resulting from a therapeutic or diagnostic procedure, the method comprising:
- administering a therapeutically effective amount of a genistein formulation to a subject prior to the therapeutic or diagnostic procedure,
- the genistein formulation comprising:
- (i) nanoparticulate genistein;
- and (ii) a pharmaceutically acceptable suspension medium comprising an aqueous carrier,
- wherein the nanoparticulate genistein exhibits a particle size distribution characterized by a D (0.50) of 0.5 μm or less, and
- wherein the nanoparticulate genistein is present in the formulation at a concentration of between 250 mg/ml and 500 mg/ml.
A method of preventing the onset of or treating acute radiation syndrome, the method comprising:
- administering a therapeutically effective amount of a genistein formulation to a subject prior to the subject being exposed to radiation greater than 0.3 Gray or 30 rads,
- the genistein formulation comprising:
- (i) nanoparticulate genistein;
- and (ii) a pharmaceutically acceptable suspension medium comprising an aqueous carrier,
- wherein the nanoparticulate genistein exhibits a particle size distribution characterized by a D (0.50) of 0.5 μm or less, and
- wherein the nanoparticulate genistein is present in the formulation at a concentration of between 250 mg/ml and 500 mg/ml.
Dependencies are inferred from the claim text.